Farmaci off label e sperimentazione clinica: l’emergenza CoViD-19 svela le potenzialità del dato normativo

Francesca Cerea


CoViD-19 emergency brings to the forefront a subject that has always been little investigated such as clinical trial and administration of off-label drugs. This paper aims to assess, through the analysis of the main measures taken by the Italian and European medicines agencies (AIFA and EMA), the ability of the regulation on the subject to cope with a constantly evolving emergency framework and to respond to several application problems that the exceptional epidemiological situation forces us to face.


CoViD-19; pandemic emergency; off label; clinical trial; medicines agencies

Full Text:

PDF (Italiano)



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

ISSN 2284-4503

Editor University of Trento

Registered by the Tribunal of Trento (act n. 6 11 April 2014)

Cookie Policy